Literature DB >> 20534773

Trimetazidine inhibits pressure overload-induced cardiac fibrosis through NADPH oxidase-ROS-CTGF pathway.

Xuehui Liu1, Yingli Gai, Fei Liu, Wei Gao, Youyi Zhang, Ming Xu, Zhaoping Li.   

Abstract

AIMS: Cardiac fibrosis contributes to the transition from compensated ventricular hypertrophy to heart failure, which can be promoted by connective tissue growth factor (CTGF). Trimetazidine (TMZ), an anti-angina drug, also has benefits in non-ischaemic heart disease. We wondered whether TMZ has an effect on cardiac fibrosis from pressure overload by downregulating CTGF. METHODS AND
RESULTS: Male Sprague-Dawley rats underwent transverse aortic constriction (TAC) or sham operation and then after 20 weeks were assigned to receive TMZ or saline for another 5 weeks. TMZ significantly inhibited collagen accumulation, CTGF expression, and reactive oxygen species (ROS) production induced by TAC. Furthermore, the effects of TMZ on ROS, the upstream signal of CTGF synthesis signal transduction, were evaluated in cardiac fibroblasts. The result showed that the ROS level was reduced by TMZ on stimulation with angiotensin II. Additionally, the NADPH oxidase activity was ameliorated with TMZ by the regulation of translocation of its subunit Rac1.
CONCLUSION: TMZ effectively inhibits myocardial fibrosis, perhaps through the NADPH oxidase-ROS-CTGF signalling pathway. Our findings may be used to provide new clues for the potential function of TMZ in pressure overload-induced myocardial fibrosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20534773     DOI: 10.1093/cvr/cvq181

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  21 in total

1.  LOX-1 abrogation reduces cardiac hypertrophy and collagen accumulation following chronic ischemia in the mouse.

Authors:  J Lu; X Wang; W Wang; H Muniyappa; C Hu; S Mitra; B Long; K Das; J L Mehta
Journal:  Gene Ther       Date:  2011-09-22       Impact factor: 5.250

Review 2.  Heart failure and loss of metabolic control.

Authors:  Zhao V Wang; Dan L Li; Joseph A Hill
Journal:  J Cardiovasc Pharmacol       Date:  2014-04       Impact factor: 3.105

3.  The C-terminal module IV of connective tissue growth factor, through EGFR/Nox1 signaling, activates the NF-κB pathway and proinflammatory factors in vascular smooth muscle cells.

Authors:  Raúl R Rodrigues-Diez; Ana Belen Garcia-Redondo; Macarena Orejudo; Raquel Rodrigues-Diez; Ana Maria Briones; Enrique Bosch-Panadero; Gyorgy Kery; Janos Pato; Alberto Ortiz; Mercedes Salaices; Jesus Egido; Marta Ruiz-Ortega
Journal:  Antioxid Redox Signal       Date:  2015-01-01       Impact factor: 8.401

4.  Metabolic Therapy in Heart Failure.

Authors:  Yury Lopatin
Journal:  Card Fail Rev       Date:  2015-10

5.  Curcumin attenuates cardiac fibrosis in spontaneously hypertensive rats through PPAR-γ activation.

Authors:  Zhe Meng; Xin-hui Yu; Jun Chen; Ling Li; Sheng Li
Journal:  Acta Pharmacol Sin       Date:  2014-08-18       Impact factor: 6.150

6.  Influence of remote ischemic conditioning on radial artery occlusion.

Authors:  Miao Liu; Qingzan Kong; Xiaojun Cai; Guohai Su
Journal:  Heart Vessels       Date:  2019-03-05       Impact factor: 2.037

7.  Trimetazidine does not alter metabolic substrate oxidation in cardiac mitochondria of target patient population.

Authors:  M Cavar; M Ljubkovic; C Bulat; D Bakovic; D Fabijanic; J Kraljevic; N Karanovic; Z Dujic; C J Lavie; U Wisloff; J Marinovic
Journal:  Br J Pharmacol       Date:  2016-03-06       Impact factor: 8.739

Review 8.  The effect of nutraceuticals on multiple signaling pathways in cardiac fibrosis injury and repair.

Authors:  Parinaz Zivarpour; Željko Reiner; Jamal Hallajzadeh; Liaosadat Mirsafaei; Zatollah Asemi
Journal:  Heart Fail Rev       Date:  2022-01       Impact factor: 4.214

9.  The formation and stabilization of a novel G-quadruplex in the 5'-flanking region of the relaxin gene.

Authors:  Sen Lin; Huiping Gu; Ming Xu; Xiaojie Cui; Youyi Zhang; Wei Gao; Gu Yuan
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

Review 10.  Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease.

Authors:  Piotr Chrusciel; Jacek Rysz; Maciej Banach
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.